⌕
Regencell Bioscience Holdings · RGC · Nasdaq
Tenet 30 · Weak
Compare
$5.10+3.24%At closeTenet 30 · Weak
$5.10+0.16 (+3.24%)
At close: Nov 16, 2026, 9:44 AM ET· Nasdaq · USD

Regencell Bioscience Holdings (RGC) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Business enginePre-revenue: no positive revenue in any year through FY26, so the growth and margin read is withheld. Worth your attention in FY26: Returns vs FCF (n/m). Visible in the receipts below.
The lines that matter · FY22–FY26
Revenue ($M)—
0.0
FY22→FY26CAGR —
Net income ($M)▼226.5%
−11.7
FY22→FY26CAGR —
Free cash flow ($M)▼135.6%
−7.7
FY22→FY26CAGR —
What the receipts whisper · what a headline number hides
Share count
+1.6%

486.6mn → 494.6mn diluted shares since FY22. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$0.0K

−100.0% YoY in FY26.

Returns vs FCF
n/m

$1.8M returned vs $−7.7M of FCF in FY26. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY22–FY26
Where every revenue dollar goes · FY26 ($M)0.0Revenue0.0COGS0.0Gross profit−1.3R&D−10.4SG&A−11.7Op income0.0Tax & other−11.7Net income

Margin trend · direction beats level
108530%sector median net margin ~4%FY22FY26

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY22–FY26 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemFY26 †FY26FY25FY24FY23FY22YoYCAGR 22→26
Revenue & profitability
Revenue
0.00.00.00.00.00.0——
Cost of revenue
0.00.00.00.00.00.0——
Gross profit
0.00.00.00.00.00.0——
Research & development
1,299.61,299.6948.31,066.21,581.62,512.2▲37.0%−15.2%
Selling, general & admin
10,418.310,418.32,813.73,545.14,429.45,080.3▲270.3%+19.7%
Total operating expenses
11,724.511,724.53,770.04,736.76,273.77,617.8▲211.0%+11.4%
Operating incomefeeds ROC rank
−11,724.5−11,724.5−3,770.0−4,736.7−6,273.7−7,617.8▼211.0%—
Other income, net
22.522.5185.8373.5211.323.2——
Pretax income
−11,701.9−11,701.9−3,584.2−4,363.2−6,062.3−7,594.6▼226.5%—
Income tax
0.00.00.00.00.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−11,701.9−11,701.9−3,584.2−4,363.2−6,062.3−7,594.6▼226.5%—
Per share
Diluted EPSbuyback-sensitive
——A—A—A—A—A——
Diluted shares (mn)
494.60494.60494.49494.49494.49486.62▲0.0%+0.4%
Margins
† FY26 = fiscal 2026, through 2026-06-30; the trailing year is not available.A Withheld by our checks.
FY19 – FY21 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-10-07 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.